CHEK1 and cancer: Accumulating evidence demonstrated that aberrant activation of DDR proteins (ATM, ATR, DNA-PK, Chk1, Chk2 and PARP) in cancer is strongly correlated with resistance to genotoxic anti-tumor therapeutics of cancer cells [3].